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 • HbA1c levels were measured using a point-of-care device (Bayer’s 
A1CNow®). This device is certified by US National Glycohemoglobin 
Standardization Program.
 • To assess PROs, patients completed the following questionnaires (in their 
preferred language) – the Audit of Diabetes-Dependent Quality of Life 
(ADDQoL),6,7 the Diabetes Treatment Satisfaction Questionnaire (DTSQ),8,9 
the Hypoglycemia Fear Survey (HFS-II)10,11 worry subscale and the European 
Quality of Life-5 Dimensions (EQ-5D).12 
 • The ADDQoL, DTSQ, HFS-II worry subscale and EQ-5D have previously 
been linguistically validated including cultural adaptation involving forward 
and back translation, with author review of back translations, revisions as 
needed, clinician review of revision, cognitive debriefing with patients and 
international harmonisation.
Patient characteristics
 • 5,817 patients were recruited across nine different countries (Belgium, 
n=659; France, n=760; Germany, n=808; Greece, n=374; Italy, n=752; 
The Netherlands, n=611; Spain, n=752; Turkey, n=600; UK, n=501). The 
proportion of patients from each participating country with a BMI ≥30 is 
shown in Figure 1. 
 • Patient characteristics according to categories of BMI can be found in  
Table 1. 
 
 
 
 • Obesity is a major modifiable risk factor in the prevention of type 2 diabetes 
(T2D). The prevalence of T2D has been shown to increase with increasing 
body mass index (BMI).1 In the US adult population nearly one-quarter of 
adults with diabetes have poor glycaemic control, and nearly half of all adult 
patients with diabetes are considered obese.1
 • In Europe, the prevalence of obesity has been reported to range from 4.0% 
to 28.3% in men and from 6.2% to 36.5% in women, with greater prevalence 
in countries in Eastern Europe and the Mediterranean than in countries in 
Western and Northern Europe.2
 • It is well established that patients with T2D are at an increased risk of 
cardiovascular disease (CVD),3 as are patients with obesity.4 Patients with 
T2D who are also obese have increased frequencies of dyslipidaemia, 
hypertension, and microalbuminuria, which are well-known cardiovascular 
risk factors.5
 • PANORAMA is a large European, multicentre, multinational, cross-sectional 
study (NCT00916513) of patients with T2D aimed at assessing treatment 
satisfaction, quality of life (QoL) and other patient-reported outcomes (PROs) 
in relation to glycaemic control. All patients received diet/exercise advice and 
most patients were treated with glucose-lowering therapies. This analysis 
compares results between obese (BMI ≥30) and non-obese (BMI <30) 
patients.
 • To achieve a representative sample of primary care physicians that reflected 
country-specific clinical practices, a random selection procedure was applied 
to databases of primary care physicians taking care of patients with T2D in 
each country. Comprehensive lists of physicians were obtained (whenever 
possible using data from national authorities, local scientific societies or 
professional associations). Where necessary, the proposed selection strategy 
was adapted to the specific characteristics of some countries leading to the 
inclusion of specialists in Italy and Greece specifically.
 • Patients with T2D were then randomly or consecutively selected from these 
physician practices. Informed consent was obtained before inclusion.
 • Study population: Patients aged ≥40 years, with a diagnosis of T2D for >1 year 
prior to study entry and an available medical record at the clinic of >1 year.
 • Key exclusion criteria: Patients with type 1 diabetes and/or a history of 
diabetic ketoacidosis, or secondary diabetes (including disease of the 
exocrine pancreas, endocrinopathies or drug-induced).
 • At the study visit, information was collected from participating patients and 
from their medical records (with a maximum retrospect of 2 years). 
 • Data collected included patient socio-demographics, disease-related 
variables, biological measures, (including HbA1c, measured using a standard 
device [see following bullet]), PROs, health-economic variables, physician-
reported endpoints, and physician socio-demographics. An electronic case 
report form (paper version also available) was provided for the collection, 
monitoring and processing of these data. All study procedures were carried 
out in accordance with Good Clinical Practice.
Introduction
Methods
Assessments
Treatment goals
A greater number of patients with BMI <30 met targets for glycaemic control (HbA1c 
<7%; p<0.001), blood pressure (<130/80 mmHg; p<0.001) and lipids  
(LDL-c <100 mg/dL; p=0.052) than patients with a BMI ≥30 (Figure 2). 
 
Treatment patterns
 • Figure 3 shows that significantly more patients with a BMI <30 were treated 
with diet alone (p=0.001) compared with patients with a BMI ≥30. In 
contrast, significantly more patients with a BMI ≥30 were treated with three 
oral antidiabetes agents (OADs) alone, or with insulin ± OAD than patients 
with a BMI <30 (p=0.019 and p=0.001, respectively). A significantly greater 
number of patients with BMI <30 were rated by their physician to have good 
adherence to lifestyle and medication compared with patients with a BMI 
≥30 (both p<0.001; Figure 3).
 
 
 
 
 
 
Results
 • Patients with a BMI ≥30 were more concerned about hypoglycaemia than 
patients with a BMI <30 (mean scores 13.72 vs 12.88 [out of a maximum  
of 72]).
 • The health status reported by patients with a BMI <30 was significantly 
better (p<0.001) than that reported by patients with a BMI ≥30  
(72.60 vs 68.08, respectively [scale 0 to 100]).
 • Patients with a BMI ≥30 reported a significantly more negative impact of 
diabetes on their QoL, less satisfaction with treatment and lower health 
status, than patients with a BMI <30 (all p<0.001). They were also more 
concerned about hypoglycaemia than patients with a BMI <30.
 • Significantly more patients with a BMI ≥30 were treated with three OADs 
or with insulin ± OAD than patients with a BMI <30. However, this is not 
explained by disease duration as patients with a BMI <30 had a significantly 
longer disease duration compared with patients with a BMI ≥30 (p<0.001).
 • These comparative analyses are unadjusted, further analyses are needed to 
adjust for confounding factors.
 
 
Patient-reported outcomes 
 • Figure 4 compares the PRO measures in the PANORAMA study between 
obese and non-obese patients. The overall mean of the ADDQoL  
average-weighted impact (AWI) score was significantly more negative for 
patients with a BMI ≥30 (-1.80) compared with patients with a BMI <30 
(-1.59, p<0.001) indicating that patients with a BMI ≥30 rated their QoL as 
more negatively impacted by diabetes than patients with a BMI <30. 
 • Patients with a BMI ≥30 were significantly less satisfied (29.36 [possible 
maximum of 36]) with their treatment (DTSQ-6 items) compared with 
patients with a BMI <30 (30.09, p<0.001; Figure 4). Physicians also rated the 
treatment satisfaction of patients with a BMI ≥30 significantly lower (p<0.001) 
than patients with a BMI <30 (27.30 vs 28.14, respectively; Figure 4).
Discussion
 • Obesity in patients with T2D was associated with a greater prevalence of  
co-morbidities (depressive and sleep disorders), microvascular 
complications, and poorer glycaemic, lipid and blood pressure control. 
 • Physicians rated obese patients as much less adherent to lifestyle advice 
and somewhat less adherent to medication. 
 • PRO measures showed more negative responses in obese patients. 
 • These results highlight the importance of effective weight management in the 
treatment of patients with T2D, and suggest that improved efforts to tailor 
treatments to individual profiles may be beneficial for obese patients. 
Conclusions
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Figure 1. Proportion of patients with a BMI ≥30
Figure 2. Goal attainment according to categories of BMI 
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Figure 4. Patient-reported outcome measures according to categories of BMI 
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Figure 3. Treatment patterns and levels of physician-reported treatment adherence according to  
categories of BMI
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Table 1. Patient characteristics according to categories of BMI 
 BMI <30 BMI >30 p-value
Participants; N (%) 3,165 (54.4) 2,650 (45.6) 
Age (years); mean (±SD) 67.25 (10.4) 64.23 (10.1) <0.001
Male; N (%) 1,861 (58.8) 1,262 (47.6) <0.001
Leaving full time education >18y; N (%) 797 (25.2) 576 (21.7) <0.001
Current smoker; N (%) 495 (15.6) 338 (12.8) 0.002
Diabetes duration; mean (±SD) 9.23 (7.4) 8.49 (6.8) <0.001
Microvascular complications; N (%) 846 (26.7) 809 (30.5) 0.001
Depressive disorders; N (%) 375 (11.9) 425 (16.0) <0.001
Sleep disorders; N (%) 369 (11.7) 464 (17.5) <0.001
For Personal and Private Study
